EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile

Yuval Cohen, Andrew Kolodziej, Marshall Morningstar iD

Obesity · 2024

DOI: 10.1002/oby.24019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Obesity, 2024. Verfasst von Yuval Cohen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA. Hauptthemen laut MEDLINE: Rimonabant, United States Food and Drug Administration, Anti-Obesity Agents, Suicide. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting the cannabinoid type 1 receptor (CB1) is a clinically validated antiobesity therapeutic approach. The only such drug approved, rimonabant, was launched in 2006 in Europe but subsequently rejected by the US Food and Drug Administration (FDA) in 2007. The FDA cited the increased risk of suicidality in its opposition to rimonabant's approval, leading to the drug's eventual worldwide withdrawal and the abandonment of this class of therapeutics. Seventeen years later, a new class of CB1‐targeting drugs is emerging, but the impact of the 2007 FDA decision remains a formidable obstacle to its clinical development. We revisit the suicidality data presented by the FDA in light of the evolution of suicidality assessment and cross‐reference this with the data in the subsequently published clinical trials. We conclude that the publicly available data do not support the FDA's conclusion that the use of rimonabant was associated with an increase in the risk of suicidality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RimonabantUnited States Food and Drug AdministrationAnti-Obesity AgentsSuicideHumansUnited StatesObesityReceptor, Cannabinoid, CB1Cannabinoid Receptor AntagonistsDrug ApprovalPyrazolesPiperidines

Substanzen

RimonabantAnti-Obesity AgentsReceptor, Cannabinoid, CB1Cannabinoid Receptor AntagonistsPyrazolesPiperidines

Autor:innen und Institutionen

  • Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA.

ORCID-Profile: Marshall Morningstar

Zitieren

APA

Cohen, Y., Kolodziej, A., & Morningstar, M. (2024). Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. https://doi.org/10.1002/oby.24019

Vancouver

Cohen Y, Kolodziej A, Morningstar M. Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. 2024. doi:10.1002/oby.24019

BibTeX
@article{Cohen2024,
  author = {Cohen, Yuval and Kolodziej, Andrew and Morningstar, Marshall},
  title = {Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24019}
}
Kostenlos starten →